Sanofi 
Bernard Davitian
Deputy Vice President of Strategy and Business DevelopmentMr Gregory Fond
Associate Director, External Innovation
Shire Pharmaceuticals
Kerry Flynn
Vice President of Intellectual PropertyRandall Morin
Director of Intellectual PropertySorrento Therapeutics Inc.
Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company has constructed antibody libraries containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets.
Mr Jaisim Shah
Chief Business Officer
Stanford Universit, School of Medicine
Daria Mochly-Rosen
Professor, Chemical and Systems Biology and Sr Associate Dean for Research
Sun Pharmaceutical Industries, Inc.
|
Sun Pharmaceutical Industries seeks strategic alliance opportunities in CNS, dermatology, oncology, ophthalmology, and respiratory therapeutic areas. Strengthening market presence while maintaining a strong customer focus is a high priority area for the company and its partners. In addition Sun has consolidated its work related to new molecules, specialty products, and innovative drug delivery systems into a subsidiary listed company, namely Sun Pharmaceuticals Advanced Research Company (SPARC). |
|
|
|
Sun Pharmaceutical Industries is a publicly traded international specialty pharma company, commercializing products in 30 markets, also a manufacturer of active pharmaceutical ingredients. In branded markets Sun’s products are prescribed in chronic therapy areas such as neurology, psychiatry, cardiology, gastroenterology, diabetology and respiratory. |
|
|
|
Sun's drive for growth has remained strong since its inception with just five (5) products in 1983. Since 1983, several milestones have been accomplished allowing Sun to emerge as an important specialty pharma company with technically complex products. In addition, Sun is the top pharmaceutical company by market capitalization in India. |
|
|
|
Within the past 15 years Sun has used a combination of internal development and external acquisitions to drive growth. Important mergers have been completed in EU, India, and U.S. including internationally approved manufacturing plants in Ohio, New Jersey, and Tennessee. |
James Hattersley
Vice President of Business DevelopmentSupernus Pharmaceuticals Inc.
Late stage specialty CNS pharmaceutical company with neurology and psych assets looking for partnerships for in and out license.
